DRNA Dicerna Pharmaceuticals Inc

Dicerna Pharmaceuticals Inc is a biopharmaceutical company. It develops ribonucleic acid interference-based pharmaceuticals for treating diseases involving liver, including rare, chronic liver, cardiovascular and viral infections.

$38.18  -0.08 (-0.20%)
As of 12/06/2021 15:59:55 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/30/2014
Outstanding shares:  78,129,378
Average volume:  5,518,225
Market cap:   $2,978,291,889
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    253031108
ISIN:        US2530311081
Sedol:      BJ62Z07
Valuation   (See tab for details)
PE ratio:   -24.02
PB ratio:   27.66
PS ratio:   15.44
Return on equity:   -115.58%
Net income %:   -64.53%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy